Principal Securities’s VanEck Biotech ETF BBH Stock Holding History

Principal Securities’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-72	Closed	-$11.9K	–	1546
2025 Q3	$11.9K	Hold	72	–	–	﹤0.01%	2646
2025 Q2	$11K	Hold	72	–	–	﹤0.01%	2584
2025 Q1	$11.3K	Hold	72	–	–	﹤0.01%	2469
2024 Q4	$11.3K	Sell	72 -100	-58%	-$16.8K	﹤0.01%	2465
2024 Q3	$30.5K	Hold	172	–	–	﹤0.01%	1912
2024 Q2	$29K	Sell	172 -225	-57%	-$36.8K	﹤0.01%	1876
2024 Q1	$66K	Hold	397	–	–	﹤0.01%	1441
2023 Q4	$65.6K	Buy	+397	New	+$61.1K	﹤0.01%	1361

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

Principal Securities's BBH Position: Q4 2025 in Review

Principal Securities sold out of VanEck Biotech ETF (BBH) in Q4 2025, closing a stake of 72 shares — an estimated $11.9K sold.

Principal Securities first reported a position in BBH in Q4 2023 and held it in 8 quarters. The position peaked at $66K in Q1 2024. 111 funds tracked by Wall St. Rank hold BBH as of Q4 2025.

Principal Securities reported no remaining VanEck Biotech ETF position as of Q4 2025 after selling out during the quarter.
Principal Securities sold 72 VanEck Biotech ETF shares in Q4 2025, an estimated $11.9K.
Principal Securities first reported a position in VanEck Biotech ETF in Q4 2023 and held it in 8 quarters.
Principal Securities's VanEck Biotech ETF position peaked at $66K in Q1 2024.
111 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.